Evidence map›Paper›PMID 31701492›Full record

ArticleCellular oncology (Dordrecht, Netherlands)2020

Loss of SPINT2 expression frequently occurs in glioma, leading to increased growth and invasion via MMP2.

Márcia Santos Pereira, Sónia Pires Celeiro, Ângela Margarida Costa, Filipe Pinto, Sergey Popov, Gisele Caravina de Almeida, Júlia Amorim, Manuel Melo Pires, Célia Pinheiro, José Manuel Lopes and 6 more

Abstract read
In one paragraph

Article in Cellular oncology (Dordrecht, Netherlands), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. AJournal of gastrointestinal oncology · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 10 institutions in 3 countries.

Márcia Santos PereiraLife and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus de Gualtar, 4710-057, Braga, Portugal.
Sónia Pires CeleiroLife and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus de Gualtar, 4710-057, Braga, Portugal.
Ângela Margarida CostaI3S - Instituto de Investigação e Inovação em Saúde, Porto, Portugal.
Filipe PintoLife and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus de Gualtar, 4710-057, Braga, Portugal.
Sergey PopovDepartment of Cellular Pathology, University Hospital of Wales, Cardiff, United Kingdom.
Gisele Caravina de AlmeidaDepartment of Pathology, Barretos Cancer Hospital, S. Paulo, Brazil.
Júlia AmorimDepartment of Oncology, Hospital de Braga, Braga, Portugal.
Manuel Melo PiresUnity of Neuropathology, Centro Hospitalar Universitário Porto, Porto, Portugal.
Célia PinheiroDepartment of Neurosurgery, Centro Hospitalar Universitário Porto, Porto, Portugal.
José Manuel LopesIPATIMUP - Institute of Molecular Pathology and Immunology, University of Porto, Porto, Portugal.
Mrinalini HonavarDepartment of Pathology, Hospital Pedro Hispano, Matosinhos, Portugal.
Paulo CostaDepartment of Radiotherapy, Hospital de Braga, Braga, Portugal.
José PimentelLaboratory of Neuropathology, Hospital de Santa Maria, Lisbon, Portugal.
Chris JonesDivisions of Molecular Pathology and Cancer Therapeutics, Institute of Cancer Research, London, United Kingdom.
Rui Manuel ReisLife and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus de Gualtar, 4710-057, Braga, Portugal. rreis@med.uminho.pt.
Marta Viana-PereiraLife and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus de Gualtar, 4710-057, Braga, Portugal. martavianap@gmail.com.
University of Minho · PTCentro Hospitalar do Porto · PTHospital Braga · PTHospital de Câncer de Barretos · BRi3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto · PTHospital de Santa Maria · PTHospital de São João · PTHospital Pedro Hispano · PTInstitute of Cancer Research · GBUniversity Hospital of Wales · GB

Funding

Fundação para a Ciência e a Tecnologia DL 57/2016/CP1360/CT0009Fundação para a Ciência e a Tecnologia NORTE-01-0145-FEDER-000013 and NORTE-01-0145-FEDER-000023 supported by the Northern Portugal Regional Operational Programme (NORTE 2020), under the Portugal 2020 Partnership Agreement, through the European Regional Development Fund (FEDER); POCI-01-0145-FEDER-007038 FEDER through the Competitiveness Factors Operational Programme (COMPETE)Fundação para a Ciência e a Tecnologia PTDC/SAU-ONC/115513/2009_FCOMP-01-0124-FEDER-015949; PTDC/SAU-TOX/114549/2009Fundação para a Ciência e a Tecnologia SFRH/BPD/104290/2014Fundação para a Ciência e a Tecnologia SFRH/BPD/115730/2016Liga Portuguesa Contra o Cancro BOLSA LIGA PORTUGUESA CONTRA CANCRO (LPCC)/Fundação PT 2018National Institute for Health Research NIHR Biomedical Research Centre at The Royal Marsden and the ICR
6 · The paper itself

Abstract

purposeHigh-grade gliomas (HGG) remain one of the most aggressive tumors, which is primarily due to its diffuse infiltrative nature. Serine proteases and metalloproteases are known to play key roles in cellular migration and invasion mechanisms. SPINT2, also known as HAI-2, is an important serine protease inhibitor that can affect MET signaling. SPINT2 has been found to be frequently downregulated in various tumors, whereby hypermethylation of its promoter appears to serve as a common mechanism. Here, we assessed the clinical relevance of SPINT2 expression and promoter hypermethylation in pediatric and adult HGG and explored its functional role.

methodsA series of 371 adult and 77 pediatric primary HGG samples was assessed for SPINT2 protein expression (immunohistochemistry) and promoter methylation (methylation-specific PCR) patterns. After SPINT2 knockdown and knock-in in adult and pediatric HGG cell lines, a variety of in vitro assays was carried out to determine the role of SPINT2 in glioma cell viability and invasion, as well as their mechanistic associations with metalloprotease activities.

resultsWe found that SPINT2 protein expression was frequently absent in adult (85.3%) and pediatric (100%) HGG samples. The SPINT2 gene promoter was found to be hypermethylated in approximately half of both adult and pediatric gliomas. Through functional assays we revealed a suppressor activity of SPINT2 in glioma cell proliferation and viability, as well as in their migration and invasion. These functions appear to be mediated in part by MMP2 expression and activity.

conclusionsWe conclude that dysregulation of SPINT2 is a common event in both pediatric and adult HGG, in which SPINT2 may act as a tumor suppressor.

Indexed as

AdolescentAdultAgedAged, 80 and overCell Line, TumorCell MovementCell ProliferationCell SurvivalChildChild, PreschoolDNA MethylationFemaleGene Expression Regulation, NeoplasticGene Knockdown TechniquesGliomaHumansHydroxamic AcidsMatrix Metalloproteinase 2Matrix Metalloproteinase InhibitorsMembrane GlycoproteinsMMP2 protein, humanN-hydroxy-2-((4-phenylphenyl)sulfonylpropan-2-yloxyamino)acetamideSPINT2 protein, humanSulfonesGliomaHypermethylationMetalloproteasesSPINT2

Identifiers

PMID31701492
PMCPMC12990697
OpenAlexW2986888064

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.